Gilead and Precision Biosciences Collaborates to Develop and Commercialize therapies for the Treatment of HBV using ARCUS Technology

 Gilead and Precision Biosciences Collaborates to Develop and Commercialize therapies for the Treatment of HBV using ARCUS Technology

Gilead Signs a License Agreement with Zydus and Dr. Reddy’s for Remdesivir to Treat COVID-19

Shots:

  • Gilead will be paying Precision $445M as a milestone payment at specific development stages in addition to the double digit royalties (<19%) from sales
  • Under the agreement, Precision will manage development, formulation & preclinical evaluation of nucleases whereas, Gilead will do clinical development & commercialization of therapies
  • The cccDNA (covalently closed circular DNA) allows HBV replication as the presently used treatment doesn’t remove the virus completely while the ARCUS will eliminate HBV cccDNA in vitro form the body
  • Currently ~257M people are affected with HBV infection, these therapies will help in advancing the treatment for HBV using Precision’s proprietary genome editing platform ARCUS technology

Click here to read full press release/ article | Ref: Gilead | Image: Ticker Talk

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post